| Health / Medical Topics |
Recombinant dHER2 Vaccine
A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. (NCI Thesaurus)
YOU MAY ALSO LIKE
Recombinant form of endogenous delta-chemokine family.
Connective Tissue-Activating Peptide III is a platelet-derived growth factor that stimulates in fibroblasts mitogenesis, extracellular matrix synthesis, glucose metabolism, and plasminogen activator…
A recombinant peptide hormone chemically identical to or similar to human polypeptide hormone corticotropin (adrenocorticotropic hormone; ACTH). Secreted by the anterior pituitary…
Glycoprotein growth factors produced by monocytes, macrophages, or activated lymphocytes that stimulate the proliferation of bone marrow cells and differentiation of stem…
Formulated therapeutic analogs of one of a number of endogenous small polypeptide cytokines with potential antineoplastic activity. Synthesized by macrophages, endothelial cells,…
A recombinant sialidase fusion protein composed of a sialidase catalytic domain derived from Actinomyces viscosus, a constituent of the normal oral and…
